Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting

VANCOUVER , May 24, 2017 /CNW/ – Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that it will be presenting two Trials in Progress posters describing the innovative Phase 1 clinical designs for its Chk1 inhibitor, SRA737, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago on June 5 th. These ongoing trials were recently amended to include cohort expansions of prospectively selected patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition via synthetic lethality.